Reasons for share price perking up?29 Nov 2018 13:16
Well the share price is looking perky. In my view there are three possible reasons:
1. Shareholder anticipation of a Ureka deal. NASH is a hot pharma area at the moment. It was announced yesterday that Genentech bought Jecure Therapeutics. See the very interesting article below about the Pharma race to acquire NASH
hTTp://www.pmlive.com/pharma_news/roche_enters_nash_race_with_deal_to_buy_jecure_1266324
"Roche has joined the melee of pharma companies trying to claim a share of the market for non-alcoholic steatohepatitis (NASH) drugs, cutting a deal to acquire US start-up Jecure Therapeutics."
"NASH is a hot topic in pharma development at the moment, with a host of companies vying to bring forward new treatments for the disease, which is viewed as an emerging health crisis - and an untapped pharma market."
"Some predictions put the market potential at $20bn to $35bn a year."
Now we know from the Interims that:
"Ureka, ImmuPharma's wholly owned subsidiary, based in Bordeaux, which is carrying out research into treatments for Type II diabetes and NASH (Non-Alcoholic-Steato-Hepatitis) has recently demonstrated success in recognised preclinical studies.
Following an extensive review by ImmuPharma's Board of directors, it has been decided that Ureka, whilst having exciting and innovative technologies, is not part of the ongoing strategy of ImmuPharma, which is now fully focused on utilising its resources to develop late stage assets.
As such, ImmuPharma, with its advisors, will now commence a process of considering all opportunities to divest Ureka. The intention is to allow ImmuPharma to divest Ureka, whilst still retaining an interest in any future commercial success."
2) Shareholder anticipation of more Lupuzor news.
YoungHarry has stated "Mid November / early December, full analyses of PIII trial" and
"The company will receive the full data from the PIII trial by the of end July / mid August, analysis will take a further two months and answers to key research issues will take a further two months after that. The key research findings will be published in peer reviewed journals."
3) Misplaced shareholder anticipation
Take your pick.